Geron Plans to Present at Upcoming Investor Conferences

Rhea-AI Summary

Geron (Nasdaq: GERN) said members of management will present at three investor events in early March 2026: TD Cowen (fireside chat) on March 2, 2026 in Boston, Barclays (fireside chat) on March 10, 2026 in Miami, and Leerink Partners in-person meetings on March 11, 2026 in Miami.

A live and archived audio webcast of each fireside chat will be available via the Investors & Media section of Geron’s website at www.geron.com.

News Market Reaction – GERN

-5.85%

4 alerts

-5.85% News Effect

-$69M Valuation Impact

$1.11B Market Cap

1.4x Rel. Volume

On the day this news was published, GERN declined 5.85%, reflecting a notable negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $69M from the company's valuation, bringing the market cap to $1.11B at that time.

Data tracked by StockTitan Argus on the day of publication.

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:

• TD Cowen 46th Annual Healthcare Conference
  Fireside Chat on Monday, March 2 at 1:10 p.m. ET in Boston, MA
  
  
• Barclays 28th Annual Global Healthcare Conference
  Fireside Chat on Tuesday, March 10 at 10:30 a.m. ET in Miami, FL
  
  
• Leerink Partners Global Healthcare Conference
  In-Person Meetings on Wednesday, March 11 in Miami, FL

A live and archived audio webcast of each fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO^® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

FAQ

When will Geron (GERN) present at the TD Cowen 46th Annual Healthcare Conference?

Geron will present a fireside chat on Monday, March 2, 2026 at 1:10 p.m. ET. According to the company, management will appear in Boston and the session will be available as a live and archived audio webcast on the company website.

What is the schedule for Geron (GERN) at the Barclays 28th Annual Global Healthcare Conference?

Geron is scheduled for a fireside chat on Tuesday, March 10, 2026 at 10:30 a.m. ET. According to the company, the event takes place in Miami and the audio webcast will be posted live and archived on Geron’s investor site.

Will Geron (GERN) hold investor meetings at the Leerink Partners Global Healthcare Conference?

Yes. Geron management will conduct in-person meetings on Wednesday, March 11, 2026 in Miami. According to the company, these are scheduled investor meetings separate from the webcasted fireside chats earlier in the week.

How can investors access Geron (GERN) conference webcasts and archives?

Investors can access live and archived audio webcasts via Geron’s website Investors & Media section at www.geron.com. According to the company, the fireside chats will be posted there for live listening and later archive playback.

What topics will Geron (GERN) management cover during the March 2026 investor events?

The company announced management presentations and meetings but did not list specific topics. According to the company, the sessions are investor-facing presentations and meetings; details on presentation content will be provided during each conference appearance.